At present, the pharmacist is faced with a perplexing number of potential drug interactions as they relate to patient care. The purpose of the investigation was to evaluate current drug-drug interaction literature, specifically gastrointestinal drug interactions. Literature search and review evaluated the authoritative basis on which conclusions were made. From this, a review was written to illustrate fallacies and misconceptions that could be derived from the literature with the intent it would serve as a guide in interpreting and evaluating drug-drug interactions. The overall study illustrates the vast need for careful evaluation of drug interaction literature before erroneous recommendations are made on conceivably inconclusive clinical studies.
Get full access to this article
View all access options for this article.
References
1.
American Pharmaceutical Association: Evaluations of Drug Interactions — 19731st Ed, American Pharmaceutical Association, Washington, DC, 1973.
2.
HanstenP. D.: Drug Interactions, 2nd Edition, Lea and Febiger, Philadelphia, 1973.
3.
MartinE. W.: Hazards of Medications, J. B. Lippincott Company, Philadelphia, 1971.
4.
BergmanF.: Influence of Cholestyramine on Absorption and Excretion of Thyroxin in Syrian Hamsters, Acta Endocrinol53: 256–263 (Oct.) 1966.
5.
NorthcuttR. C.: The Influence of Cholestyramine on Thyroxin Absorption, J. Am. Med. Assoc.208: 1857–1861 (June 9) 1969.
6.
GalloD. G.: The Interaction Between Cholestyramine and Drugs, Proc. Soc. Exp. Biol. Med.120: 60–65 (Oct.) 1965.
7.
GrossL.BrotmanM.: Hypoprothrombinemia and Hemorrhage Associated with Cholestyramine Therapy, Ann. Intern. Med.72: 95–96 (Jan.) 1970.
8.
CasdorphH. R.: The Efficacy and Safety of Cholestyramine Therapy in Hyperlipidemic Patients, Ann. Intern. Med.74: 818 (May) 1971.
9.
BazzanoG.BazzanoG. S.: Digitalis Intoxication: Treatment with a New Steroid-binding Resin, J. Am. Med. Assoc.220: 828–830 (May 8) 1972.
10.
CaldwellJ. H.: Interruption of the Enterohepatic Circulation of Digitoxin by Cholestyramine, J. Clin. Invest.50: 2638–2644 (Dec.) 1971.
11.
ChengS. J.WhiteA.: Effect of Orally Administered Neomycin on the Absorption of Penicillin, N. Engl. J. Med.267: 1296–1297 (Dec. 20) 1962.
12.
GoodmanL. S.GilmanA. (Eds): The Pharmacological Basis of Therapeutics, 4th Edition, Macmillan, New York, 1970, p. 1284.
13.
KastrupE. K. (Ed): Facts and Comparisons.Facts and Comparisons, Inc., 1973, p. 351.
14.
O'ReillyR. A.AggelerP. M.: Determinants of the Response to Oral Anticoagulant Drugs in Man, Pharmacol. Rev.22: 35–96 (Mar.) 1970.
15.
MartinW. J.: Hemorrhagic Diathesis Induced by Antimicrobials, J. Am. Med. Assoc.205: 192 (July 15) 1968.
16.
ForrestF. M.: Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients, Biol. Psychiat.2: 53–58 (Jan.) 1970.
17.
FannW. E.: The Effects of Antacids on the Blood Levels of Chlorpromazine, Clin. Pharmacol. Ther.14: 135 (Jan.-Feb.) 1973.
18.
RiegelmanS.: Griseofulvin — Phenobarbital Interaction in Man, J. Am. Med. Assoc.213: 426–431 (July 20) 1970.
19.
GoldmanH.DeposituF.: Hypoprothrombinemic Bleeding in Young Infants, Am. J. Dis. Child.111: 430–432 (Apr.) 1966.
20.
KlippelA. P.PitsingerB.: Hypoprothrombinemia Secondary to Antibiotic Therapy and Manifested by Massive Gastrointestinal Hemorrhage, Arch. Surg.36: 266–268 (Feb.) 1968.
21.
ChristensenL. K.SkovstedL.: Inhibition of Drug Metabolism by Chloramphenicol, Lancet2: 1397–1399 (Dec. 27) 1969.
22.
LewisR. J.: Effect of Barbiturates on Anticoagulant Therapy, N. Engl. J. Med.274: 110 (Jan. 13) 1966.
23.
LevyG.: Pharmacokinetic Analysis of the Effect of Barbiturates on the Anticoagulant Action of Warfarin in Man, Clin. Pharmacol. Ther.11: 372–377 (May-June) 1970.
24.
MichelJ. C.: Effect of Food and Antacids on Blood Levels of Aureomycin and Terramycin, J. Lab. Clin. Med.36: 632–634 (Oct.) 1950.
25.
WaisbrenB. A.HueckelJ. S.: Reduced Absorption of Aureomycin Caused by Aluminum Hydroxide, Proc. Soc. Exp. Biol. Med.73: 73–74 (Jan.) 1950.
26.
HarcourtR. S.HamburgerM.: The Effect of Magnesium Sulfate in Lowering Tetracycline Blood Levels, J. Lab. Clin. Med.50: 464–468 (Sep.) 1957.
27.
RosenblattJ. E.: Comparison of In Vitro Activity and Clinical Pharmacology of Doxycycline With Other Tetracyclines, Antimicrob. Ag. Chemother.1966, p. 134–141.
28.
ScheinerJ.AltemeierW. A.: Experimental Study of Factors Inhibiting Absorption and Effective Therapeutic Levels of Declomycin, Surg. Gynecol. Obstet.114: 9–14 (Jan.) 1962.
29.
AlbertA.ReesC. W.: Avidity of the Tetracyclines for the Cations of Metals, Nature177: 433–434 (Mar. 3) 1956.
30.
BarrW. H.: Decrease of Tetracycline Absorption in Man by Sodium Bicarbonate, Clin. Pharmacol. Ther.12: 779–784 (Sep.-Oct.) 1971.
31.
ShilsM. E.: Some Metabolic Aspects of Tetracycline. Clin. Pharmacol. Ther.3: 321–339 (May-June) 1962.
